A practical reference on incretin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-12. Anything still debated is marked as such rather than presented as settled.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Role of skin in locomotion describes how the integumentary system is involved in locomotion. Typically the integumentary system can be thought of as skin, however the integumentary system also includes the segmented exoskeleton in arthropods and feathers of birds. The primary role of the integumentary system is to provide protection for the body. However, the structure of the skin has evolved to aid animals in their different modes of locomotion. Soft bodied animals such as starfish rely on the arrangement of the fibers in their tube feet for movement. Eels, snakes, and fish use their skin like an external tendon to generate the propulsive forces need for undulatory locomotion. Vertebrates that fly, glide, and parachute also have a characteristic fiber arrangements of their flight membranes that allows for the skin to maintain its structural integrity during the stress and strain experienced during flight.
Allysine is involved in the production of elastin and collagen. Increased allysine concentration in tissues has been correlated to the presence of fibrosis. Allysine residues react with sodium 2-naphthol-6-sulfonate to produce a fluorescent bis-naphtol-allysine product. In another assay, allysine-containing proteins are reduced with sodium borohydride to give a peptide containing the 6-hydroxynorleucine (6-hydroxy-2-aminocaproic acid) residue, which (unlike allysine) is stable to proteolysis.
==== Antiquity ==== Yavne was one of the major ancient cities in the southern coastal plain, situated 20 km (12.43 mi) south of Jaffa, 15 km (9.32 mi) north of Ashdod, and 7 km (4.35 mi) east of the Mediterranean. From excavations of the ancient tell (mound created by accumulation of archaeological remains) known as Tel Yavne (Hebrew), which developed on a natural kurkar hill, the area shows to have been inhabited continuously from either the Bronze or Iron Age until the British Mandate. During some periods, especially the Byzantine period, the settlement expanded to cover part of the plain and hills surrounding the tell. Yavne is mentioned in the Bible and other ancient texts. In Roman times, the city was known as Iamnia or Jamnia. It was bequeathed by King Herod upon his death to his sister Salome. Upon her death it passed to Emperor Augustus, who ran it as a private imperial estate, a status retained for at least a century. After Salome's death, Iamnia came into the property of Livia, the future Roman empress, and then to her son Tiberius. In the 40s AD, a dispute emerged in Jamnia when Gentiles constructed a mud-brick altar to the Emperor, provoking the local Jewish population. The Jews destroyed the altar, which they saw as desecration. This led the Gentiles to complain to Capito, the imperial revenue collector in Judaea, who reported the matter to Emperor Caligula. In retaliation, Caligula ordered a statue of himself as Jupiter to be placed in the Holy of Holies at the Temple of Jerusalem. Iamnia played a role in several events during the First Jewish–Roman War.
Sources: en.wikipedia.org
=== Interferons === Both helper and cytotoxic T-cells can control viral infections by secreting interferons. Cytotoxic T cells usually kill virally infected cells. However, they can also be stimulated to secrete antiviral cytokines such as IFN-γ and TNF-α, which do not kill the cell, but limit viral infection by down-regulating the expression of viral components. DNA vaccinations can be used to curb viral infections by non-destructive IFN-mediated control. This was demonstrated for hepatitis B. IFN-γ is critically important in controlling malaria infections and is a consideration for anti-malarial DNA vaccines.
Artificial skin is a collagen scaffold that induces regeneration of skin in mammals such as humans. The term was used in the late 1970s and early 1980s to describe a new treatment for massive burns. It was later discovered that treatment of deep skin wounds in adult animals and humans with this scaffold induces regeneration of the dermis. It has been developed commercially under the name Integra and is used in massively burned patients, during plastic surgery of the skin, and in treatment of chronic skin wounds. Alternatively, the term "artificial skin" sometimes is used to refer to skin-like tissue grown in a laboratory, although this technology is still quite a way away from being viable for use in the medical field. 'Artificial skin' can also refer to flexible semiconductor materials that can sense touch for those with prosthetic limbs (also experimental).
==== Antidepressants ==== Alaproclate (GEA-654) Centpropazine Cericlamine (JO-1017) Femoxetine (Malexil; FG-4963) Ifoxetine (CGP-15210) Omiloxetine Panuramine (WY-26002) Pirandamine (AY-23713) Seproxetine ((S)-norfluoxetine)
Sources: en.wikipedia.org
Inorganic chemistry deals with synthesis and behavior of inorganic and organometallic compounds. This field covers chemical compounds that are not carbon-based, which are the subjects of organic chemistry. The distinction between the two disciplines is far from absolute, as there is much overlap in the subdiscipline of organometallic chemistry. It has applications in every aspect of the chemical industry, including catalysis, materials science, pigments, surfactants, coatings, medications, fuels, and agriculture.
Towards the end of this period the pro-independence forces made two important advances. In the Southern Cone, a veteran of the Spanish army with experience in the Peninsular War, José de San Martín, became the governor of the Province of Cuyo. He used this position to begin organizing an army as early as 1814 in preparation for an invasion of Chile. This was an important change in strategy after three United Provinces campaigns had been defeated in Upper Peru. San Martín's army became the nucleus of the Army of the Andes, which received crucial political and material support in 1816 when Juan Martín de Pueyrredón became Supreme Director of the United Provinces. In January 1817, San Martín was finally ready to advance against the royalists in Chile. Ignoring an injunction from the congress of the Río de la Plata not to move against Chile, San Martín together with General Bernardo O'Higgins Riquelme, later Supreme Director of Chile, led the Army over the Andes in a move that turned the tables on the royalists. By 10 February, San Martín had control of northern and central Chile, and a year later, after a war with no quarter, the south. With the aid of a fleet under the command of former British naval officer Thomas Cochrane, Chile was secured from royalist control and independence was declared that year. San Martín and his allies spent the next two years planning an invasion of Peru, which began in 1820.
It was thought that the heart was examined by Anubis and a variety of deities during the Weighing of the Heart ceremony. If the heart weighed more than the feather of Maat, which symbolized the ideal standard of behavior. If the scales balanced, it meant the heart's possessor had lived a just life and could enter the afterlife; if the heart was heavier, it would be devoured by the monster Ammit. The Chinese character for "heart", 心, derives from a comparatively realistic depiction of a heart (indicating the heart chambers) in seal script. The Chinese word xīn also takes the metaphorical meanings of "mind", "intention", or "core", and is often translated as "heart-mind" as the ancient Chinese believed the heart was the center of human cognition. In Chinese medicine, the heart is seen as the center of 神 shén "spirit, consciousness". The heart is associated with the small intestine, tongue, governs the six organs and five viscera, and belongs to fire in the five elements. The Sanskrit word for heart is hṛd or hṛdaya, found in the oldest surviving Sanskrit text, the Rigveda. In Sanskrit, it may mean both the anatomical object and "mind" or "soul", representing the seat of emotion. Hrd may be a cognate of the word for heart in Greek, Latin, and English. Many classical philosophers and scientists, including Aristotle, considered the heart the seat of thought, reason, or emotion, often disregarding the brain as contributing to those functions.
==== Kardashev's point of view ==== According to Kardashev, humanity's ignorance of the physical possibilities of communication through space is great. Only a negligible fraction of the electromagnetic spectrum as an existing source of information in the universe is known. Thus, of the 89% of information that humans lack, 42% concerns the range from 109 to 1014 Hz (centimetric, millimetric, submillimetric and infrared waves) and 25% concerns the range from 1015 to 1018 Hz (ultraviolet radiation and X-rays). Kardashev distinguishes two categories of listening areas: objects emitting in a broad frequency spectrum and objects emitting on the contrary in a narrow spectral line, the second category posing much more theoretical problems than the first, while being central, both for astrophysics and for the search for extraterrestrial civilizations. Despite advances in astrophysics, the available information is still insufficient to prove the absence of supercivilizations, based on the inability to observe signs of activity. However, because of the possibility that there are planetary systems much older than the Solar System, and considering that cosmic objects such as quasars could be products of supercivilization activity, a detailed program of listening and searching for intelligent signs remains valid. This program includes:
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.